These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37336713)

  • 21. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hereditary non-polyposis colorectal cancer/Lynch syndrome in three dimensions.
    Kravochuck SE; Church JM
    ANZ J Surg; 2017 Dec; 87(12):1006-1010. PubMed ID: 26990828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
    Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
    [No Abstract]   [Full Text] [Related]  

  • 24. Next Generation Sequencing in Molecular Diagnosis of Lynch Syndrome - a Pilot Study Using New Stratification Criteria.
    Kašubová I; Holubeková V; Janíková K; Váňová B; Sňahničanová Z; Kalman M; Plank L; Lasabová Z
    Acta Medica (Hradec Kralove); 2018; 61(3):98-102. PubMed ID: 30543514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discordant Staining Patterns and Microsatellite Results in Tumors of MSH6 Pathogenic Variant Carriers.
    van der Werf-'t Lam AS; Terlouw D; Tops CM; van Kan MS; van Hest LP; Gille HJP; Duijkers FAM; Wagner A; Eikenboom EL; Letteboer TGW; de Jong MM; Bajwa-Ten Broeke SW; Bleeker FE; Gomez Garcia EB; de Wind N; van Wezel JT; Morreau H; Suerink M; Nielsen M
    Mod Pathol; 2023 Sep; 36(9):100240. PubMed ID: 37307877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
    Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
    PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
    Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
    Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
    Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
    J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
    Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
    Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
    Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Nakagawa H; Sotamaa K; Prior TW; Westman J; Panescu J; Fix D; Lockman J; Comeras I; de la Chapelle A
    N Engl J Med; 2005 May; 352(18):1851-60. PubMed ID: 15872200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endometrial cancer in Lynch syndrome.
    Zhao S; Chen L; Zang Y; Liu W; Liu S; Teng F; Xue F; Wang Y
    Int J Cancer; 2022 Jan; 150(1):7-17. PubMed ID: 34398969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PREMM5 distinguishes sporadic from Lynch syndrome-associated MMR-deficient/MSI-high colorectal cancer.
    Sandoval RL; Horiguchi M; Ukaegbu C; Furniss CS; Uno H; Syngal S; Yurgelun MB
    Fam Cancer; 2023 Oct; 22(4):459-465. PubMed ID: 37572151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale for evaluating breast cancers of Lynch syndrome patients for mismatch repair gene expression.
    Sorscher S
    Breast Cancer Res Treat; 2019 Nov; 178(2):469-471. PubMed ID: 31392519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of tumor testing for Lynch syndrome identification in patients with colorectal cancer: A retrospective single-center study.
    Signoroni S; Tibiletti MG; Ricci MT; Milione M; Perrone F; Pensotti V; Chiaravalli AM; Carnevali I; Morabito A; Bertario L; Vitellaro M
    Tumori; 2019 Feb; 105(1):76-83. PubMed ID: 30117378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current clinical topics of Lynch syndrome.
    Tanakaya K
    Int J Clin Oncol; 2019 Sep; 24(9):1013-1019. PubMed ID: 29744602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS).
    Zeimet AG; Mori H; Petru E; Polterauer S; Reinthaller A; Schauer C; Scholl-Firon T; Singer C; Wimmer K; Zschocke J; Marth C
    Arch Gynecol Obstet; 2017 Jul; 296(1):123-127. PubMed ID: 28510097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of molecular diagnostics for the detection of Lynch syndrome.
    Pino MS; Chung DC
    Expert Rev Mol Diagn; 2010 Jul; 10(5):651-65. PubMed ID: 20629513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.